They have been approved for the treatment of newly diagnosed CD33 + acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), respectively, yet they are associated with increased risk of hepatotoxicity and SOS/VOD. This evidence concerns the gene CD33 and acute myeloid leukemia.